How to Read Pregnancy and Lactation Drug Labeling: A Practical Guide for 2025

When you’re pregnant or breastfeeding, every pill, injection, or prescription comes with a question: Is this safe? The old system-letters like A, B, C, D, and X-was easy to remember, but it was also misleading. It made people think a drug labeled "C" was just "a little risky," when in reality, it could mean anything from "no human data" to "serious animal findings." That’s why the FDA replaced it in 2015 with something far more useful: the Pregnancy and Lactation Labeling Rule (PLLR). Now, instead of a single letter, you get real, detailed information. But reading it? That’s not always simple.

What Changed After the FDA’s 2015 Update?

Before June 30, 2015, drug labels used five letter categories to summarize pregnancy risk. Category A meant "safe"-but only about 2% of drugs qualified. Category X meant "don’t use"-less than 1% of drugs. Most fell into C or D, which created confusion. A drug labeled "C" didn’t mean "moderate risk." It meant: "Animal studies showed problems, but we don’t have enough human data to say for sure." Many doctors and patients misread it as a grade, not a warning.

The PLLR scrapped those letters entirely. Now, every prescription drug’s label has three new sections under "Use in Specific Populations":

• 8.1 Pregnancy
• 8.2 Lactation
• 8.3 Females and Males of Reproductive Potential

Each section follows the same structure: Risk Summary, Clinical Considerations, and Data. No more guessing. Just facts-backed by studies, numbers, and real-world observations.

How to Read the Pregnancy Section (8.1)

Start with the Risk Summary. This isn’t vague. It tells you:

• The background risk of birth defects in any pregnancy (about 3%)
• The background risk of miscarriage (10-20%)
• Whether the drug increases those risks, and by how much

For example, a label might say: "Exposure to this drug in the first trimester is associated with a 1.5-fold increased risk of neural tube defects compared to the background rate of 0.1% to 0.2%." That’s not "maybe risky." That’s: "Out of 1,000 pregnancies, you’d expect 1-2 cases of neural tube defects normally. With this drug, you might see 1.5 to 3."

Next, check the Clinical Considerations. This is where you find action steps:

• "Monitor fetal growth every 4 weeks after 20 weeks gestation"
• "Avoid use in the third trimester due to risk of neonatal withdrawal"
• "Consider switching to an alternative during the first trimester if possible"

These aren’t suggestions. They’re based on clinical evidence. If a drug causes withdrawal in newborns, the label will tell you exactly when the risk peaks-and what to watch for.

Finally, the Data section gives you the source: "Prospective cohort study of 1,200 pregnant women exposed during the first trimester; adjusted odds ratio 1.8 (95% CI 1.3-2.5)." You don’t need to be a researcher to understand this. It means: "We tracked 1,200 women. Those who took the drug had 1.8 times the odds of this outcome. The range is reliable-we’re 95% sure it’s between 1.3 and 2.5 times higher."

How to Read the Lactation Section (8.2)

Breastfeeding parents face the same question: "Will this drug get into my milk? Will it hurt my baby?" The old system didn’t answer that at all. The PLLR does.

The Risk Summary tells you:

• How much of the drug passes into breast milk (usually as a percentage of the mother’s dose)
• Whether the infant’s blood levels are measurable
• Any known effects on the baby

Example: "Maternal serum concentration of 100 ng/mL results in infant exposure of approximately 5 ng/mL, or 5% of the maternal dose. No adverse effects reported in 50 breastfed infants."

That’s powerful. Five percent is low. And if no babies had issues in 50 cases? That’s reassuring.

The Clinical Considerations section gives you practical advice:

• "Infant monitoring recommended for sedation or poor feeding if maternal dose exceeds 50 mg daily"
• "Timing of breastfeeding: wait 4 hours after dosing to minimize infant exposure"
• "Alternative medication with lower milk transfer preferred for neonates under 1 month"

The Data section here often includes pharmacokinetic studies-how the drug moves through the body, how long it lasts in milk, how much the baby absorbs. You’ll see terms like "milk-to-plasma ratio" (M/P ratio). A ratio under 0.5 means the drug doesn’t concentrate in milk. A ratio over 1.0 means it does. Both matter.

What About Fertility and Contraception? (Section 8.3)

This section isn’t just for women. It covers men too. If a drug can affect sperm or cause birth defects if taken by the father, it’s here.

You’ll find:

• "Pregnancy testing required before starting treatment and monthly during use"
• "Two forms of contraception required, with failure rate less than 1% per year"
• "Discontinue drug 3 months before attempting conception due to long half-life"
• "Potential for reversible infertility in males at doses above 20 mg/day"

This isn’t filler. It’s critical. Some antidepressants, acne medications, and cancer drugs can impact fertility or harm a developing embryo-even if the father is taking them.

Why This Matters More Than Ever

Since the PLLR launched, pregnancy exposure registries have exploded. In 2014, only about 5,000 pregnancies were tracked annually. By 2023, that number jumped to over 25,000. Why? Because now, drug labels require manufacturers to list active registries. That means more data, faster answers.

For example, if you’re on an antiepileptic and pregnant, your doctor can point you to a registry that’s already tracked 2,000 similar cases. You’re not alone. And you’re not guessing.

The FDA reports that misinterpretation of pregnancy risk dropped from 68% under the letter system to 31% under the new narrative format. That’s a huge win.

But there’s a catch. The new labels are longer-300 to 500 extra words per drug. A 2018 study found 62% of obstetricians felt overwhelmed at first. Family doctors were even more challenged: 57% said they felt less confident prescribing after the change.

That’s why tools like MotherToBaby and TERIS exist. They translate the labels into plain language. Many pharmacies now have pharmacists trained in maternal health. And the FDA offers a free mobile app called "PLLR Navigator"-search a drug, get the key points in seconds.

What to Do When You’re Overwhelmed

You don’t need to memorize every label. Here’s how to handle it:

1. Check the Risk Summary first. Does it mention a specific risk increase? If yes, note the number.
2. Look at Clinical Considerations. Are there clear "do this" or "avoid this" instructions? Those are your action items.
3. Ask: Is there a registry? If yes, call or visit the website. You can enroll and get updates.
4. Use trusted resources. MotherToBaby (1-866-626-6847) and TERIS (teris.org) offer free, expert advice.
5. Don’t panic over relative risk. A "2-fold increase" sounds scary-but if the baseline risk is 1%, now it’s 2%. That’s still low.

Many drugs have safer alternatives. If you’re worried, ask: "Is there another option with less milk transfer or no known fetal risk?" Often, there is.

What’s Coming Next?

The FDA is working on visual aids. By 2025, you might see icons next to drug labels: a tiny baby with a red X, a milk drop with a green check, or a clock showing "avoid in third trimester." These are being tested now.

Also, more data is being collected. In 2022, the FDA required all new drug applications to include lactation pharmacokinetics. That means future labels will be even more precise.

But gaps remain. A 2023 report found 63% of psychiatric drug labels still lack specific timing info-like "avoid in first trimester due to heart defect risk." That’s changing, but slowly.

Bottom Line

The new system isn’t perfect. It’s not quick. But it’s honest. It doesn’t hide behind a letter. It tells you what’s known, what’s uncertain, and what to watch for. If you’re pregnant, breastfeeding, or planning to be, you’re not just a patient-you’re a partner in your care. Learn how to read the label. Use the tools. Ask questions. Your health-and your baby’s-depends on it.